Condition: Corneal Neovascularization · Sponsor: Price Vision Group
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
This description comes directly from the study's public registry record.
Marianne Price, PhD · 317-814-2990 · mprice@cornea.org
Always discuss trial participation with your own doctor first.
| Price Vision Group | Indianapolis, Indiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04787471